Literature DB >> 33552024

Genome-Wide Analysis of Staphylococcus aureus Sequence Type 72 Isolates Provides Insights Into Resistance Against Antimicrobial Agents and Virulence Potential.

Nayab Batool1, Amen Shamim1, Akhilesh Kumar Chaurasia1,2, Kyeong Kyu Kim1,2,3.   

Abstract

Staphylococcus aureus sequence type 72 (ST72) is a major community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) that has rapidly entered the hospital setting in Korea, causing mild superficial skin wounds to severe bloodstream infections. In this study, we sequenced and analyzed the genomes of one methicillin-resistant human isolate and one methicillin-sensitive human isolate of ST72 from Korea, K07-204 and K07-561, respectively. We used a subtractive genomics approach to compare these two isolates to other 27 ST72 isolates to investigate antimicrobial resistance (AMR) and virulence potential. Furthermore, we validated genotypic differences by phenotypic characteristics analysis. Comparative and subtractive genomics analysis revealed that K07-204 contains methicillin (mecA), ampicillin (blaZ), erythromycin (ermC), aminoglycoside (aadD), and tetracycline (tet38, tetracycline efflux pump) resistance genes while K07-561 has ampicillin (blaZ) and tetracycline (tet38) resistance genes. In addition to antibiotics, K07-204 was reported to show resistance to lysostaphin treatment. K07-204 also has additional virulence genes (adsA, aur, hysA, icaABCDR, lip, lukD, sdrC, and sdrE) compared to K07-561, which may explain the differential virulence potential of these human isolates of ST72. Unexpectedly, the virulence potential of K07-561 was higher in an in vivo wax-worm infection model than that of K07-204, putatively due to the presence of a 20-fold higher staphyloxanthin concentration than K07-204. Comprehensive genomic analysis of these two human isolates, with 27 ST72 isolates, and S. aureus USA300 (ST8) suggested that acquisition of both virulence and antibiotics resistance genes by ST72 isolates might have facilitated their adaptation from a community to a hospital setting where the selective pressure imposed by antibiotics selects for more resistant and virulent isolates. Taken together, the results of the current study provide insight into the genotypic and phenotypic features of various ST72 clones across the globe, delivering more options for developing therapeutics and rapid molecular diagnostic tools to detect resistant bacteria.
Copyright © 2021 Batool, Shamim, Chaurasia and Kim.

Entities:  

Keywords:  Staphylococcus aureus; antibiotics resistance; sequence type 72; subtractive genomics; virulence factors

Year:  2021        PMID: 33552024      PMCID: PMC7854921          DOI: 10.3389/fmicb.2020.613800

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  66 in total

1.  The structure of a Staphylococcus aureus leucocidin component (LukF-PV) reveals the fold of the water-soluble species of a family of transmembrane pore-forming toxins.

Authors:  J D Pédelacq; L Maveyraud; G Prévost; L Baba-Moussa; A González; E Courcelle; W Shepard; H Monteil; J P Samama; L Mourey
Journal:  Structure       Date:  1999-03-15       Impact factor: 5.006

Review 2.  Molecular mechanisms of antibiotic resistance.

Authors:  Jessica M A Blair; Mark A Webber; Alison J Baylay; David O Ogbolu; Laura J V Piddock
Journal:  Nat Rev Microbiol       Date:  2014-12-01       Impact factor: 60.633

3.  Coagulases as determinants of protective immune responses against Staphylococcus aureus.

Authors:  Molly McAdow; Andrea C DeDent; Carla Emolo; Alice G Cheng; Barry N Kreiswirth; Dominique M Missiakas; Olaf Schneewind
Journal:  Infect Immun       Date:  2012-07-23       Impact factor: 3.441

4.  Nonconventional Therapeutics against Staphylococcus aureus.

Authors:  Caroline M Grunenwald; Monique R Bennett; Eric P Skaar
Journal:  Microbiol Spectr       Date:  2018-11

5.  First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin.

Authors:  Ayaka Tsukimori; Itaru Nakamura; Sakiko Okamura; Akihiro Sato; Shinji Fukushima; Yasutaka Mizuno; Tetsuo Yamaguchi; Tetsuya Matsumoto
Journal:  BMC Infect Dis       Date:  2014-08-23       Impact factor: 3.090

6.  Glyceryl trinitrate blocks staphyloxanthin and biofilm formation in Staphylococcus aureus.

Authors:  Hisham A Abbas; Ahmed M Elsherbini; Moutaz A Shaldam
Journal:  Afr Health Sci       Date:  2019-03       Impact factor: 0.927

7.  Staphylococcus aureus synthesizes adenosine to escape host immune responses.

Authors:  Vilasack Thammavongsa; Justin W Kern; Dominique M Missiakas; Olaf Schneewind
Journal:  J Exp Med       Date:  2009-09-28       Impact factor: 14.307

Review 8.  Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors?

Authors:  François Vandenesch; G Lina; Thomas Henry
Journal:  Front Cell Infect Microbiol       Date:  2012-02-16       Impact factor: 5.293

9.  A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics.

Authors:  Vannakambadi K Ganesh; Jose J Rivera; Emanuel Smeds; Ya-Ping Ko; M Gabriela Bowden; Elisabeth R Wann; Shivasankarappa Gurusiddappa; J Ross Fitzgerald; Magnus Höök
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

10.  Complete genome sequence of a Pantón-Valentine leukocidin-negative community-associated methicillin-resistant Staphylococcus aureus strain of sequence type 72 from Korea.

Authors:  Yan Chen; Som S Chatterjee; Stephen F Porcella; Yun-Song Yu; Michael Otto
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

View more
  1 in total

1.  Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant Enterococcus faecium in a Hollow Fiber Infection Model.

Authors:  Shuaishuai Wang; Huiping Liu; Jun Mao; Yu Peng; Yisong Yan; Yaowen Li; Na Zhang; Lifang Jiang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.